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Abstract
Background: Osteoarthritis (OA) is the most common joint disorder in the United States of America (USA) with a
fast-rising prevalence. Current treatment modalities are limited, and total knee replacement surgeries have shown
disadvantages, especially for grade II/III OA. The interest in the use of biologics, including umbilical cord (UC)-
derived Wharton’s jelly (WJ), has grown in recent years. The results from a preliminary study demonstrated the
presence of essential components of regenerative medicine, namely growth factors, cytokines, hyaluronic acid (HA),
and extracellular vesicles, including exosomes, in WJ. The proposed study aims to evaluate the safety and efficacy of
intra-articular injection of UC-derived WJ for the treatment of knee OA symptoms.
Methods: A randomized, controlled, single-blind, multi-center, prospective study will be conducted in which the
safety and efficacy of intra-articular administration of UC-derived WJ are compared to HA (control) and saline
(placebo control) in patients suffering from grade II/III knee OA. A total of 168 participants with grade II or III knee
OA on the KL scale will be recruited across 53 sites in the USA with 56 participants in each arm and followed for 1
year post-injection. Patient satisfaction, Numeric Pain Rating Scale, Knee Injury and Osteoarthritis Outcome Score,
36-Item Short Form Survey (SF-36), and 7-point Likert Scale will be used to assess the participants. Physical exams,
X-rays, and MRI with Magnetic Resonance Observation of Cartilage Repair Tissue score will be used to assess
improvement in associated anatomy.
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Discussion: The study results will provide valuable information into the safety and efficacy of intra-articular
administration of Wharton’s jelly for grade II/III knee osteoarthritis. The results of this study will also add to the
treatment options available for grade II/III OA as well as help facilitate the development of a more focused
treatment strategy for patients.
Trial registration: ClinicalTrials.gov, NCT04711304. Registered on January 15, 2021
Keywords: Umbilical cord, Wharton’s jelly, Knee osteoarthritis, Regenerative medicine, Biologics, Randomized
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Background
Osteoarthritis (OA) is the most common joint disorder in
the United States of America (USA), affecting approxi-
mately 12% of US adults aged between 25 and 74 years
[1]. By 2030, the number of US adults with arthritis is ex-
pected to reach 67 million, leading to a continuous in-
crease in the number of total knee replacement surgeries
[2–4]. While total knee replacement surgeries have shown
advantages, avoiding or delaying such surgery is usually
desirable, for medical reasons and health care system per-
spective [5]. The long-term outcomes after total knee re-
placement surgeries for patients with grade II or III knee
OA on the Kellgren-Lawrence (KL) scale are worse com-
pared to patients with grade IV OA [6, 7]. Additionally,
conventional treatment modalities, including activity
modification, physical therapy, and pharmacological
agents such as non-steroidal anti-inflammatory drugs, cor-
ticosteroids, viscosupplementation, and narcotics, have
limitations and potential side effects [8–16]. Thus, there is
a need for alternative intervention for patients with grade
II or III knee OA.
Interest in the use of biologics for regenerative medicine
applications has increased over the last decade [17–22]. To
be compliant with the relevant laws and regulations in the
US biologics that adhere to the US Food and Drug Admin-
istration regulation of Human Cells, Tissues, and Cellular
and Tissue-Based Products (HCT/P’s) regulated under title
21, part 1271 of the Code of Federal Regulations, must
meet all the conditions under section 361 of Public Health
Safety Act to be regulated solely under this section [17, 23].
According to this regulation, HCT/P’s must meet the cri-
teria of being minimally manipulated, for homologous use
only, not to be combination products, to have no systemic
effect, and to be non-dependent on the metabolic activity
of the living cells [17]. Despite the increased use, there is in-
sufficient literature assessing the amount of growth factors
(GFs), cytokines (CKs), hyaluronic acid (HA), and extracel-
lular vesicles (EVs), including exosomes, present in these
products, and more specifically, umbilical cord (UC)-de-
rived Wharton’s jelly (WJ). In addition, there is limited or
no literature assessing the safety and efficacy of UC-derived
WJ products via a randomized, controlled, multi-center
study.
We formulated a novel UC-derived WJ product that
has been shown to contain the essential components of
regenerative medicine, namely GFs, CKs, HA, and EVs
[24]. In addition, the Wharton’s jelly has been reported
to contain high amounts of extracellular matrix compo-
nents, including collagen, hyaluronic acid, and sulfated
proteoglycans, required to improve the treatment effect
[24]. That study was an essential preliminary step to bet-
ter characterize the WJ formulation before performing
clinical trials to determine its safety and efficacy includ-
ing providing symptomatic relief to patients with grade
II or III knee OA.
The goal of the proposed study is to evaluate the safety
and efficacy of intra-articular injection of UC-derived
WJ for the treatment of knee OA symptoms. We
hypothesize that there will be no difference in the out-
comes in patients receiving injection of UC-derived WJ,
HA, or saline in terms of safety. We also hypothesize
that patients receiving intra-articular injection of WJ will
show an improvement in their overall satisfaction, Nu-
meric Pain Rating Scale (NPRS), Knee Injury and Osteo-
arthritis Outcome Score (KOOS), and cartilage
formation over a period of 1 year compared to the base-
line visit. Our null hypothesis is that there is no differ-
ence in patients receiving either WJ, HA, or saline, and
no difference between baseline and after treatment
within each treatment group over a period of 1 year.
Methods and analysis
This study protocol is reported in accordance with the
Standard Protocol Items: Recommendations for Inter-
vention Trials (SPIRIT) criteria [25, 26].
Study setting
This multi-center study involves up to 53 sites consisting
of health care centers, community clinics, and academic
hospitals in the USA.
Study design
This is a randomized, controlled, single-blind, multi-
center, prospective study in which the safety and efficacy
of intra-articular UC-derived WJ are compared to HA
(control) and saline (placebo control) in patients
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suffering with knee OA. The participants in the treat-
ment arm will receive a 2-mL intra-articular injection of
UC-derived WJ (GeneXSTEM, BioIntegrate Inc., Law-
renceville, GA, USA, diluted with 1:1 sterile normal sa-
line). The participants in the control arm and placebo
arm will receive 4 mL HA (Monovisc®—4 mL injection
with 22mg/mL HA, Anika Therapeutics, Bedford, MA,
USA) and 4 mL of sterile normal saline, respectively. Pa-
tients in the HA group or saline group will be offered
the opportunity to cross over to the Wharton’s jelly
group after 3 months, as a method to aid in study re-
cruitment and retention (Fig. 1).
Participants
A total of 168 patients with grade II or III knee OA on
the KL scale will be recruited with 56 patients in each
arm. Participation will be discussed with patients who
meet the inclusion criteria. The patients will be given
the opportunity to read an informed consent form (ICF)
and obtain answers to all questions before considering
participation at the enrollment/baseline visit.
Inclusion criteria
Consenting adult patients over the age of 18 years diag-
nosed with grade II or grade III (mild or moderate) OA
on the KL scale (in only one knee) will be considered for
this study along with the following inclusion criteria:
 Body mass index (BMI) of <50kg/m2.
 Ability to comply with requirements of study visits.
 Pain score of 4 or more on the Numeric Pain Rating
Scale (NPRS).
 Female patients must be abstinent, surgically
sterilized, or postmenopausal.
 Premenopausal females must have a negative
pregnancy test, on contraceptive measures, and do
not anticipate pregnancy during the duration of the
study.
 Males with premenopausal female partners will have
to take contraceptive measures for the duration of
the study.
 Be willing and capable of giving written informed
consent to participate.
 Be willing and capable of complying with study-
related requirements, procedures, and visits.
Exclusion criteria
Patients will be excluded from the enrollment in the
study if they meet any of the following exclusion criteria:
 Patients who have taken any pain medication
including non-steroidal anti-inflammatory drugs
(NSAIDs) within 2 weeks prior to study injection
date
 Patients who use anticoagulants, have a substance
abuse history, and/or fail to agree not to take any
knee symptom-modifying drugs during the course of
the study without discussing and reporting the use
to the site principal investigator and study team
 Positive on special tests and/or stability tests on
physical exam
 Patients with intra-articular injection of any drug in-
cluding corticosteroids and viscosupplementation in
the index knee in the last 3 months
 Surgery on the index knee within the last 6 months
 Traumatic injury to the index knee within the last 3
months
 Planned elective surgery during the course of the
study
 History of organ or hematologic transplantation,
rheumatoid arthritis, or other autoimmune disorders
 Patients on immunosuppressive medications/
treatment
 Patients with a diagnosis of non-basal cell carcinoma
within the last 5 years
 Patients with knee infection or who used antibiotics
for knee infection within the last 3 months
 Patients who participated in another clinical trial or
treatment with any investigational product within
the last 30 days prior to the inclusion in the study
 Female patients who are breastfeeding or are
pregnant or desire to be pregnant or become
pregnant during the course of the study
 Contraindications to radiographic or MRI imaging
 Serious neurological, psychological, or psychiatric
disorders
 Other medical conditions including any
malignancies determined by the site principal
investigator as interfering with the study
 Injury or disability claims under current litigation or
pending or approved workers’ compensation claims
Participants can voluntarily withdraw from the study at
any time. Withdrawal from the study will not affect the
patient’s access to other treatments nor will the patient be
subjected to any sanctions. Participation in the study may
be terminated if continued participation in the study is
not in the subject’s best interest, according to the principal
investigator’s opinion or if the subject withdraws partici-
pation. Determination of therapy cessation and need of
explanation will be performed by the principal investigator
(PI) based on the standard medical practice. Any patient
who suffers an adverse event whether or not related to
treatment may withdraw voluntarily.
Randomization
Participants will be assigned to a treatment group using
sealed opaque envelopes coded with an alphanumeric
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Fig. 1 Summary of the trial design
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identifier to ensure consecutive allocation of envelopes.
Block randomization across all sites will be used to en-
sure even distribution to each group of 1:1:1 allocation
to the 3 study arms—WJ, HA, and saline.
Study interventions
After completion of visit 1 (preliminary/baseline), and
determination of patient’s eligibility to be enrolled in the
study, participants will be randomized into one of the
three arms of the study and be scheduled for the proced-
ure visit. At this visit, the participants will either receive
an intra-articular injection of WJ (treatment), HA (con-
trol), or saline (placebo control). Following the proced-
ure, the participants will be periodically followed for 1
year. After the 3-month follow-up visit, patients injected
with HA or saline will be offered the opportunity to
cross over to the WJ group. If they decide to cross over,
they will receive an injection of WJ and will follow the
schedule of events for the WJ injection group beginning
immediately after the injection follow-up visit.
Assessment points
Assessments for the study period will begin at visit 1
(preliminary/baseline). The patients will be assessed
using the inclusion/exclusion criteria for eligibility in the
study. The participants will then undergo a physical
exam (PE) on the knee diagnosed with grade II/III OA,
as well as a baseline plain radiograph for an up-to-date
OA grade on the KL scale and a T2-weighted MRI to
obtain a Magnetic Resonance Observation of Cartilage
Repair Tissue (MOCART) score. The participants will
also be required to complete baseline case report forms
(CRFs) including the Numeric Pain Rating Scale (NPRS),
Knee Injury and Osteoarthritis Outcome Score (KOOS),
and patient satisfaction/survey, SF-36. Demographic in-
formation and medical history will also be collected. The
participants will then be assessed for any adverse events
at visit 2.2, immediately following their respective intra-
articular injection, and at their procedure visit (visit 2.1)
and be re-assessed for pain using the NPRS. Through
visit 3 (24 h follow-up), visit 4 (48 h follow-up), and visit
5 (1 week follow-up), patients will be reassessed for pain
using the NPRS. On visit 5 (1 week follow-up), visit 6 (6
weeks follow-up), and visit 7 (3 months follow-up), par-
ticipants will undergo another PE as well as have their
NPRS, KOOS, and 7-point Likert scale recorded. Plain
radiographs will be taken on visits 6 and 7. At this point
of the study, patients in the HA or saline arms will be
offered the opportunity to cross over to the WJ arm and
will follow the schedule of events beginning at visit 2.2.
On visit 8 (6 months follow-up) and visit 9 (1 year
follow-up), patients will undergo a PE as well as have
their NPRS, KOOS, 7 point Likert scale, and SF-36 taken
and recorded. In addition, plain radiographs will be
taken again followed by an MRI on visit 9 for a
MOCART score. All participants will have the oppor-
tunity to report any adverse events at each visit or at any
time within the study.
The following are the primary endpoints:
1. To determine the safety of umbilical cord-derived
Wharton’s jelly formulation (GeneXSTEM™)
2. To assess the patient satisfaction
The following are the secondary endpoints:
a. To assess the change in patient-reported outcome
measures, NPRS and KOOS, from baseline and be-
tween the groups at different time points
b. To assess the cartilage formation via MOCART at 1
year time point and compare it from baseline and
between the groups
Sample size and statistical analysis
A sample size calculation based on the initial analysis of
change from baseline to 3 months was computed to de-
termine the number needed per group to detect signifi-
cance at the α = 0.05 level. To detect differences of 8–10
units in the KOOS, considered as the minimum clinical
important difference (MCID), assuming an α of 0.05, β
of 90%, and a 2-tailed test, the estimated sample size was
calculated to be at least 40 subjects in each group, in-
creased to 56 subjects in each group to allow for loss to
follow-up. An interim analysis at the initial 3-month
follow-up will allow us to examine the effect size and in-
crease enrollment if necessary. The data will also be ana-
lyzed based on the age group, gender, and grade of
osteoarthritis.
Data collection and handling
All source documents will be maintained by the PI. Data
will be transcribed on study CRFs, and the original data
will be secured by the PI and made available to the
sponsor and study monitors. The PI will maintain re-
cords for 5 years. All CRF pages will be subjected to the
initial inspection for omitted data, data inconsistencies,
illegible data, and deviations by the study monitors. All
hard copies of CRFs and media will be stored in a secure
location. The PI will be responsible for submitting the
following data and reports:
 Adverse events (AEs): on an ongoing basis via the
proper section of the CRF.
 Severe adverse events (SAEs) will be reported within
24 h of knowledge of the event to the sponsor and
reported to IRB within 5 days, as per regulations.
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 Any deviations, exceptions, and violations of
protocol will be reported to the sponsor within 5
days and reported to IRB per their regulations.
 A protocol progress report will be provided to the
sponsor and IRB as per regulations.
 A study closure report will be provided to the
sponsor and IRB as per regulations.
Quality control and assurance
All documents and data will be produced and main-
tained in such a way as to ensure control of documents
and data to protect patients’ privacy as far as reasonably
practicable. The sponsor, study monitor, and representa-
tives of regulatory authorities are permitted to access the
study documents (protocol, CRFs, medical records/files)
as needed.
Discussion
OA is a debilitating condition that affects millions of pa-
tients across the world, and it is estimated to drastically
increase in prevalence in the upcoming years [1, 27]. OA
can lead to marked pain, loss of independence, and sig-
nificant health care costs [27, 28]. Currently, there are
several non-operative treatment options available for
grade II/III knee OA that aim to help reduce pain and
enhance the quality of life, but unfortunately fail to re-
solve the underlying pathophysiological process of OA.
These are the several reasons why the field of regenera-
tive medicine and the use of biologics including UC-
derived WJ has increased so profoundly.
The proposed clinical trial will be one of the first to
examine the safety and efficacy of intra-articular admin-
istration of WJ compared to HA and saline in patients
with grade II/III OA. Studies have demonstrated the effi-
cacy of HA injections in controlling the signs and symp-
toms of OA, specifically in terms of pain and function,
and reported safety and efficacy for the treatment of
pain of OA of the knee in patients who have failed to ad-
equately respond to conservative non-pharmacological
therapy and simple analgesics such as acetaminophen
[29, 30]. In addition, a recent study by Farr et al. also
utilized HA as a control demonstrating the superiority
of amniotic suspension allograft over HA and saline for
modification of knee OA symptoms [5]. A recent meta-
analysis also details the safety and efficacy of HA com-
pared to corticosteroids for knee OA [31]. Thus, HA
was chosen as a control for this proposed study.
On the other hand, despite the widespread use of HA,
there is inconsistency in clinical studies pertaining to the
effect of HA in knee OA. More randomized controlled
trials with larger data set are required to test the efficacy
of HA versus other established therapies of OA. Thus,
both the Osteoarthritis Research Society International
2012 guideline and the American College of
Rheumatology 2013 guidelines neither recommend nor
discourage the use of HA [32]. Due to these reasons, this
study is designed with an intent-to-treat, and therefore,
the participants receiving HA or saline will be offered
the opportunity to cross over to the Wharton’s jelly
group after 3 months. Furthermore, the anecdotal evi-
dence and unpublished case report from our team dem-
onstrated that one injection is sufficient. The
aforementioned study by Farr et al. also utilized one in-
jection [5]. Therefore, in this study, we also proposed to
utilize one injection only.
We anticipate that this study will demonstrate that
intra-articular administration of WJ is safe. Some min-
imal adverse effects can be observed. The adverse events
associated with the intra-articular administration of
Wharton’s jelly will be similar to inherent risks associ-
ated with any intra-articular injection. These include
pain and/or reaction at the injection site, failure of ther-
apy to work as expected, infections, potential for con-
tamination of the product, and unknown or unexpected
reactions, including but not limited to immunogenic re-
actions, tumorigenic reactions, and development of auto-
immune disorders. We also anticipate that patients
suffering from grade II/III OA will experience improve-
ment in their pain, function, quality of life, and overall
satisfaction. In addition, we foresee that articular cartil-
age formation will increase over the 1-year period of the
study in comparison with the baseline visit. This study
has several limitations. The present investigation was de-
signed as single-blinded rather than double-blinded. The
concept of a double-blinded study was abandoned as the
treating investigators can easily detect the difference in
viscosity between the injectables used. Nevertheless,
most of the endpoints in the study will be patient-
reported, thus reducing the bias from the unblinded in-
vestigators. Another limitation of the study is the
utilization of only one HA formulation: we are aware
that the HA formulations with different molecular
weights or cross-linking are available. Thus, the results
from this study may not be applicable to other HA for-
mulations. In conclusion, the results of this study will
add to our understanding of the treatment options avail-
able for grade II/III OA and help facilitate the develop-
ment of a more focused treatment strategy for patients
with grade II/III OA.
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